Use of Circulating Tumor DNA for the Clinical Management of Metastatic Castration-Resistant Prostate Cancer: A Multicenter, Real-World Study

CONCLUSIONS: Our study explored the genomic landscape of Chinese patients with mCRPC at different treatment stages using minimally invasive methods and evaluated the clinical implications of the driver genomic alterations on patients' response to the most widely used therapies for mCRPC. We observed a significantly higher alteration frequency of CDK12 in our cohort compared with the SU2C-PCF cohort.PMID:33990090 | DOI:10.6004/jnccn.2020.7663

Source: Journal of the National Comprehensive Cancer Network : JNCCN - May 14, 2021 Category: Cancer & Oncology Authors: Baijun Dong Liancheng Fan Bin Yang Wei Chen Yonghong Li Kaijie Wu Fengbo Zhang Haiying Dong Huihua Cheng Jiahua Pan Yinjie Zhu Chenfei Chi Liang Dong Jianjun Sha Lei Li Xudong Yao Wei Xue Source Type: research